Myeloid Therapeutics.
Bayanan da aka gabatar a AACR 2022 sun nuna cewa Myeloid ya tsara kuma ya haɓaka dandamali na hanyoyin warkewa biyu, ATAK ™ CAR masu karɓa da kuma shirye-shiryen vivo mRNA, don ƙaddamarwa da kunna ikon ƙwayoyin myeloid don kai hari kan kansa ta hanyar sake fasalin rigakafi. Kwayoyin Myeloid sune farkon mawaƙa na amsawar rigakafi kuma suna taruwa ta halitta a cikin ciwace-ciwacen ciwace-ciwacen daji, a wasu lokuta suna wakiltar kashi saba'in da biyar na ƙwayar ƙwayar cuta. Sabuntawar Myeloid na mRNA don sashin myeloid suna faɗaɗa tasirin waɗannan ƙwayoyin cuta a cikin gwaje-gwajen vivo.
Littafin labari na Myeloid na CARs, wanda aka sani da ATAK™ Receptors, yana haɗu da sanin ƙari tare da yankuna masu siginar rigakafi da yawa. Masana kimiyyar Myeloid sun bincika haɗaɗɗun sigina na rigakafi da yawa waɗanda ba a tantance su ba da kuma gano mafi kyawun hanyoyin sigina da yawa. Haɗin sanin ciwon daji yana ɗaure tare da waɗannan sabbin wuraren siginar siginar ciki na ciki yana ba da damar sel myeloid su sake tsara su tare da haɗaɗɗun siginar rigakafi waɗanda ba a gano su a baya ba, wanda ke haifar da kashe ƙwayar cuta da faɗaɗa martanin rigakafin ƙwayar cuta.
Littafin labari na Myeloid a cikin dandalin injiniya na vivo musamman yana hari da kunna sel myeloid don fitar da mafi girman rigakafin cutar kansa. Ta wannan hanyar, Myeloid yana nuna cewa isar da ƙwayoyin lipid-nanoparticles (LNPs) suna haifar da sakamako na mRNA a cikin zaɓin ɗauka da magana ta sel myeloid a cikin vivo, wanda ke haifar da kashe kumburi mai ƙarfi a cikin nau'ikan ciwon sanyi da yawa. Waɗannan bayanan suna nuna yuwuwar fasahar Myeloid don tsara sel kai tsaye a cikin vivo.
"A taron AACR na wannan shekara, mun yi farin cikin gabatar da gagarumin ci gaba a duk faɗin dandamalin mu wanda ke nuna ikon ƙwayoyin myeloid don tsara manyan martanin rigakafi ta hanyar shirye-shiryen mRNA da kuma ATAK™ CARs na gaba," in ji Bruce McCreedy, Ph. D., Babban Jami'in Kimiyya na Myeloid. "Wadannan bayanan suna goyan bayan shirye-shiryen mu na ƙaddamar da gwaje-gwaje na asibiti don kimanta aminci da ayyukan 'yan takarar samfuran magunguna da yawa a cikin shekara mai zuwa, faɗaɗa bututun mu na asibiti."
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Bayanan da aka gabatar a AACR 2022 sun nuna cewa Myeloid ya ƙirƙira kuma ya haɓaka dandamali biyu na sabbin hanyoyin warkewa, masu karɓar ATAK ™ CAR da shirye-shiryen vivo mRNA, don yin niyya da kunna ikon ƙwayoyin myeloid don kai hari kan kansa ta hanyar sake fasalin rigakafi.
- Ta wannan hanyar, Myeloid yana nuna cewa isar da ƙwayoyin lipid-nanoparticles (LNPs) suna haifar da sakamako na mRNA a cikin zaɓin ɗauka da magana ta ƙwayoyin myeloid a cikin vivo, wanda ke haifar da kashe ƙari mai ƙarfi a cikin nau'ikan ciwon sanyi da yawa.
- Haɗin sanin cutar kansa yana ɗaure tare da waɗannan sabbin wuraren siginar siginar intracellular suna ba da damar sake tsara ƙwayoyin myeloid tare da haɗaɗɗun siginar rigakafi waɗanda ba a gano su a baya ba, wanda ke haifar da kashe ƙwayar cuta da kuma martanin rigakafin ƙwayar cuta.
